(Please note, this Podcast was created using generative AI (GenAI), and while our Partners review and edit it for quality purposes, GenAI can sometimes make mistakes. This Podcast is for educational and entertainment purposes only. Please consult source materials directly and seek professional advice when needed.) 

This podcast provides a deep dive into the world of Artificial Intelligence (AI) within the pharmaceutical and biotechnology industries, specifically for professionals in risk, compliance, and audit. Drawing on insights from World Economic Forum reports, the podcast explores both the exciting potential of AI to revolutionise healthcare – including drug discovery, operational efficiency, and AI-enabled health – and the critical cyber security risks and governance challenges that come with this technological shift. You'll gain actionable knowledge on how to strategically use AI, manage associated risks, understand the role of AI agents, leverage generative AI for job augmentation, and navigate the evolving landscape of AI and cyber security to protect sensitive data and ensure regulatory compliance.

(Please note, this Podcast was created using generative AI (GenAI), and while our Partners review and edit it for quality purposes, GenAI can sometimes make mistakes. This Podcast is for educational and entertainment purposes only. Please consult source materials directly and seek professional advice when needed.) 

This podcast delves into the crucial role of soft skills – like leadership, communication, and problem-solving – for risk managers and compliance officers in the the pharmaceutical and biotech industries. Tired of training that doesn't translate into real-world results? We explore the challenges of making soft skills stick and go beyond traditional approaches by examining insights from behavioural science. Discover evidence-based strategies and frameworks, including the COM-B and COMPASS models, to effectively embed essential soft skills within your teams. Learn how to move from training sessions to genuine transformation, fostering collaboration, navigating complexity, and ultimately driving success in the life sciences sector.

(Please note, this Podcast was created using generative AI (GenAI), and while our Partners review and edit it for quality purposes, GenAI can sometimes make mistakes. This Podcast is for educational and entertainment purposes only. Please consult source materials directly and seek professional advice when needed.) 

This podcast delves into the critical findings of the 2025 Edelman Trust Barometer Report, specifically examining its implications for the pharmaceutical and biotech industries. It explores the current climate of global grievance and widespread distrust in institutions, and how this impacts the ability of pharma and biotech companies to operate effectively.

Key topics discussed include the erosion of employee trust in CEOs, the rising fear of discrimination and its potential consequences, and the urgent need for these industries to earn and maintain public trust – their "license to act". The podcast emphasises that traditional approaches focused solely on profit are no longer sufficient, and highlights the expectation for businesses to actively address societal concerns. 

Listeners will gain insights into the importance of transparency, accountability, and ethical conduct as cornerstones of trust-building. The podcast also offers concrete, actionable steps that leaders in risk, compliance, and audit can take within their organisations to foster a culture of trust and navigate this challenging landscape. It underscores the evolving role of CEOs as societal leaders and the necessity of a company-wide commitment to ethical practices. Ultimately, the podcast aims to equip professionals in the pharma and biotech sectors with the knowledge and strategies needed to rebuild trust, strengthen relationships, and create more resilient and successful businesses in an era of significant public scrutiny. 

(Please note, this Podcast was created using generative AI (GenAI), and while our Partners review and edit it for quality purposes, GenAI can sometimes make mistakes. This Podcast is for educational and entertainment purposes only. Please consult source materials directly and seek professional advice when needed.) 

This podcast episode provides a deep dive into recent PMCPA rulings relevant to pharmaceutical promotional practices in the UK, offering practical lessons for compliance officers. It examines case studies involving complaints against Roche regarding Vabysmo and AstraZeneca concerning Trixeo. The discussion highlights the importance of understanding how the PMCPA interprets the code, particularly in relation to implied claims and the presentation of data. Key topics explored include the significance of context in assessing the accuracy and potential for misleading interpretations of promotional materials, the need for clinical evidence to support claims of benefit beyond a drug's mechanism of action, and the careful presentation of clinical trial data, especially mortality endpoints and statistical significance. The podcast also touches upon the role of internal review processes, the importance of a culture of compliance, and the impact of external scrutiny from regulatory bodies like the FDA.

(Please note, this Podcast was created using generative AI (GenAI), and while our Partners review and edit it for quality purposes, GenAI can sometimes make mistakes. This Podcast is for educational and entertainment purposes only. Please consult source materials directly and seek professional advice when needed.) 

This podcast provides a deep dive into recent PMCPA rulings relevant for compliance officers working in UK Pharma. It highlights the challenges of staying compliant in the digital age, examining specific cases involving companies like AstraZeneca, Moderna and GSK. The discussion covers key compliance areas such as social media use by healthcare professionals, clinical trial recruitment, event presence, online platforms for healthcare professionals, and employee activity on professional networking sites like LinkedIn. Each case offers practical takeaways related to transparency, ethical considerations, advertising prescription-only medicines, presenting prescribing information, using case studies, and the importance of clear social media policies and training. The podcast emphasises the need for a proactive approach to compliance and staying informed about the latest regulatory developments.

(Please note, this Podcast was created using generative AI (GenAI), and while our Partners review and edit it for quality purposes, GenAI can sometimes make mistakes. This Podcast is for educational and entertainment purposes only. Please consult source materials directly and seek professional advice when needed.) 

Dive deep into the Institute of Risk Management's "Risk Trends 2025" report with  analysis tailored for Heads of Risk Management in the Pharma/Biotech industry... Explore emerging risks like technology, geopolitical instability, and climate change and discover actionable strategies for building resilience and proactively mitigating threats in an interconnected world. 

(Please note, this Podcast was created using generative AI (GenAI), and while our Partners review and edit it for quality purposes, GenAI can sometimes make mistakes. This Podcast is for educational and entertainment purposes only. Please consult source materials directly and seek professional advice when needed.)

The World Economic Forum's 2025 Global Risks Report marks its 20th year of analysis, and the findings are a wake-up call. This episode dives deep into the report, revealing the emerging threats that should be on every leader's radar, with a particular focus on the Pharma and Biotech sector. Prepare for a frank discussion about the 'geopolitical recession' and its practical implications for global supply chains, talent acquisition, and business operations.

We explore the escalating risks of state-based armed conflict, the rise of geoeconomic confrontation, and the urgent need for diversification and resilience. Discover how misinformation and disinformation, increasingly powered by AI, threaten to undermine trust and create instability. Learn how to protect your company from these threats through robust data security and proactive communication strategies.

This isn't just about mitigating current risks; we're also confronting the complex challenges of biotechnology. We unpack the potential for misuse of AI, the risks of advanced therapies like gene editing, and the ethical dilemmas that come with blurring the line between treatment and enhancement. The report calls for a global framework for responsible innovation in biotech to ensure these powerful tools are used for the benefit of all.

Finally, we look at the long-term implications of super-aging societies and how it will affect healthcare systems and the availability of skilled labour. The report emphasises that the risk landscape is constantly evolving, and that technological risks are becoming increasingly impactful. We need to be adaptable, agile, and willing to embrace new ways of thinking. Leaders must move from risk mitigation to risk leadership, using their expertise to shape a more equitable and sustainable future. Tune in to understand how you can harness the power of AI and biotech responsibly.

(Please note, this Podcast was created using generative AI (GenAI), and while our Partners review and edit it for quality purposes, GenAI can sometimes make mistakes. This Podcast is for educational and entertainment purposes only. Please consult source materials directly and seek professional advice when needed.) 

This podcast explores Stephen M.R. Covey's "The Speed of Trust", and its critical relevance to the pharmaceutical and biotech industries. It argues that trust is not just an ethical consideration but a key economic driver, impacting speed and cost. The podcast delves into Covey's four cores of credibility—integrity, intent, capabilities, and results—and how they form the foundation of trust. It further explores the practical application of Covey's 13 behaviors, offering a toolkit for building trust in the workplace.

(Please note, this Podcast was created using generative AI (GenAI), and while our Partners review and edit it for quality purposes, GenAI can sometimes make mistakes. This Podcast is for educational and entertainment purposes only. Please consult source materials directly and seek professional advice when needed.) 

This podcast offers a deep dive into real-world ABPI case studies from December 2024 to unpack key lessons and challenges. The podcast goes beyond the headlines to explore the nuances of the ABPI code and its application to real-world scenarios.

The podcast focuses on several crucial themes, including:

• The tension between the urgency to help patients and the need for responsible communication.
• The importance of the Early Access to Medicines Scheme (EAMS) and the strict rules surrounding communication of unapproved treatments.
• The potential for misinformation and harm when promoting unapproved indications.
• The need for robust internal review processes and clear guidelines for communicating about medicines under the EAMS.
• The critical role of whistleblower systems and fostering a culture where employees feel safe raising concerns.
• The complexities of applying the ABPI code to activities that took place before a company becomes a member, and to overseas activities.
• The need for strong controls around information access, especially in global organizations, and clear procedures for defining target audiences.
• The importance of providing clear guidance on how to handle situations that are not always black and white, particularly when responding to questions about unapproved uses.
• The necessity for transparency and clear identification of pharma representatives, particularly when using third-party vendors.
• The need for robust oversight mechanisms for third-party vendors, including regular audits and monitoring.
• The vital role of consistent documented practices and proactive risk management.

Ultimately, the podcast highlights the need for a culture of ethics throughout the entire organisation, going beyond just following the rules and truly committing to doing the right thing. The podcast emphasises that this is an ongoing journey that requires constant vigilance and a willingness to learn and adapt.